Cullinan Therapeutics, Inc. Common Stock

$13.5
USD
Last updated on --.
24h volume656.31K
24h highest15.6540 USD
24h lowest13.4660 USD
24h Price movement-6.41%

CGEM recent prices

24 Hours
-6.41%-$0.925
30 days
-8.25%-$1.215
60 days
-9.12%-$1.355
90 days
-11.79%-$1.805

Key data

Previous close14.4300 USD
Market cap1.01B USD
Volume656.31K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-3.1800 USD
Net income (FY)-221.04M USD
Revenue (FY)--
Last report dateMay 7, 2026

About Cullinan Therapeutics, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersCAMBRIDGE
Employees (FY)109.00
Net income per employee (FY)-2.03M USD
Listed onNasdaq
Official website

CGEM conversion tables

CGEMCGEM
USDUSD
0.5 CGEM6.752 USD
1 CGEM13.5 USD
5 CGEM67.52 USD
10 CGEM135.05 USD
USDUSD
CGEMCGEM
0.5 USD0.037023 CGEM
1 USD0.074047 CGEM
5 USD0.37023 CGEM
10 USD0.74047 CGEM

FAQ

CGEM is trading at $13.50, -6.41% over the last 24 hours. Track live moves on the price chart at the top of this page.
The CGEM stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. CGEM is currently trading at $13.50, -6.41% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on CGEM price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. CGEM's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from CGEM; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against CGEM's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Cullinan Therapeutics, Inc. Common Stock's market cap is currently 1.01B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume656.31K
24h highest15.6540 USD
24h lowest13.4660 USD
24h Price movement-6.41%
CGEMCGEM
USDUSD
Start trade with CGEM Perpetual